Rx Safety Cmte.’s Holmboe Sees Communication As Key To Risk Management
Executive Summary
Yale University's Eric Holmboe, MD, will be taking his second look at risk-management proposals for GlaxoSmithKline's Lotronex during the inaugural meeting of FDA's Drug Safety & Risk Management Subcommittee
You may also be interested in...
GSK Lotronex To Be Reviewed By FDA Drug Safety Cmte. In April
FDA's Drug Safety & Risk Management Subcommittee will review the safety of GlaxoSmithKline's withdrawn irritable bowel syndrome agent Lotronex (alosetron) on April 23
Lilly Forteo Osteoporosis Indication Approval Recommended With Restrictions
Lilly's Forteo should be approved for treatment of osteoporosis in postmenopausal women but restricted either to high-risk patients or second-line use, FDA's Endocrinologic and Metabolic Drugs Advisory Committee recommended July 27.
Glaxo's Lotronex Risk-Management Program Emphasizes Appropriate Use
Glaxo Wellcome is proposing an "appropriate use" campaign as the focus of its risk-management plan for Lotronex, the company told FDA's Gastrointestinal Drugs Advisory Committee June 27.